Dai­ichi and Zymeworks end an­ti­body pact af­ter sev­en years

Zymeworks and Dai­ichi Sankyo end­ed a sev­en-year col­lab­o­ra­tion on bis­pe­cif­ic an­ti­bod­ies last week.

Un­der the 2016 agree­ment, Zymeworks li­censed its Azy­met­ric and Efect plat­forms to Dai­ichi Sankyo to de­vel­op one bis­pe­cif­ic an­ti­body ther­a­py in ex­change for tech­nol­o­gy ac­cess fees and mile­stone pay­ments and roy­al­ties, ac­cord­ing to SEC fil­ings. But Zymeworks al­so got some­thing else in re­turn, in the form of li­cens­es to cer­tain im­muno-on­col­o­gy an­ti­bod­ies from Dai­ichi.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER